India is leading the world in number of diabetics and has
earned a dubious distinction of being termed as the diabetic capital of the
world. One third of the patients undergoing surgery are diabetics. It is a
known fact that diabetics undergo surgery at a higher rate than non-diabetics
and are more prone to various adverse outcomes. Many treatment modalities are
employed for metabolic control in diabetics undergoing surgery during
perioperatve period with an aim to reduce the morbidity and mortality. Among
such insulin regimes, the basal-bolus subcutaneous insulin regimen is thought
to be more physiological approach to control the hyperglycaemia in hospitalized
patients. In basal-bolus insulin regime long acting basal insulin is given to
control the hyperglycaemia overnight and short acting bolus insulin is given to
control the hyperglycaemia after meals. Though the basal-bolus insulin regimes
are employed in non-surgical situations for glycaemia control. However, there
is paucity of scientific literature regarding the clinical outcome of long
lasting basal insulin and rapid acting mealtime insulin regimes in surgical
situations. Hence, it was found worthwhile to study the clinical outcomes of
two subcutaneous split-mixed basal/bolus insulin regimes in diabetics
undergoing surgery. Therefore, this study has evaluated the clinical outcome of
two subcutaneous split-mixed regimes: Glargine as basal and Lispro as bolus
insulin versus Detemir as basal and Aspart as bolus insulin in type 2 diabetics
undergoing surgery.
Author(s) Details:
Mushtaq Ahmad,
Department of Pharmacology, Government Medical College, Doda - Jammu
& Kashmir- 182202, India.
Mohd.
Younus Shah,
Department
of Medicine, Al-Falah School of Medical Sciences & Research Centre, Dhauj,
Faridabad, Haryana – 121004, India.
Please see the link here: https://stm.bookpi.org/ANUMS-V8/article/view/13522
No comments:
Post a Comment